We describe what might have been the first reported case ofa neuroendocrine carcinoma ofthejugular foramen. A 50-year-old woman presented with progressive left-sided sensorineural hearing loss, vertigo, pulsatile tinnitus, headaches, and ataxia. Magnetic resonance imaging revealed a A-em left-sided jugular foramen tumor. The patient underwent near-total resection of the tumor. Despite lower cranial nerve preservation, postoperative paralysis of cranial nerves IX and X occurred, and vocal fold medialization was performed 5 days later. The final pathologic diagnosis was neuroendocrine carcinoma. The patient was treated with concurrent chemotherapy and intensity-modulated radiation therapy. This article will discuss the pathologicfeatures and the management of jugular foramen tumors, along with the differential diagnosis of these rare tumors.
Introduction
Jugular foramen tumors may cause lower cranial ner ve symptoms or very few clinical findings due to contral ateral cranial nerve compensation. Tumors of the temporal bone and skull base arise in three locations: (I) the mastoid or middle ear, (2) the jugular foramen, or (3) the petrous apex. Our discussion focuses on jugular foramen tumors. These tumors may be highly vascular, mayinvolveimportant neurovascular structures, and can present a diagnostic and management challenge .
Paragangliomas are themost common jugular foramen tumors.' The differential diagnosis includes schwannomas, meningiomas, chordomas, chondrosarcoma, and metastatic lesions. To our knowl edge, neuroendocrine 
Case report
On October 27, 2004, a 50-year-old woman was referred to our skull base center with a I-month history of progressive left-sided sensorineural hearing loss, vertigo, pulsatile tinnitus, headaches, and ataxia. Her medical history was significant only for diet -controlled diabetes mellitus. The pati ent denied any hoarseness or dysphagia. No lower cranial nerve deficits were identified. Audiometry showed a severe, left-sided high-frequency sensorineur al hearing loss (figure 1). Magn etic resonance imaging (MRI) with gadolinium showed a 4-cm left-sided tumor of the posterior cranial fossa adjacent to th e medial wall of the jugular foramen, with extension into the jugular foramen and likely occlusion of the sigmoid sinus (figure 2, A and B). Four-vessel cerebral angiography revealed a tumor blush in the jugular foramen (figure 3). The distal left sigmoid sinus and the internal jugular vein were occluded, and an emissary vein was identified draining off the left transverse sinus into the external jugular vein. Retrograde filling of the right transverse sinus, jugular . bulb, and jugular vein was noted.
The patient underwent near-total resection of the tumor through a left retrosigmoid craniotomy on Novembe r 9, 2004. Only a small portion of th e tumor was left within th e jugular foramen. Despite lower cranial ner ve preservation and successful stimulation at the conclusion of the sur gery, paralysis ofleft cranial ner ves IX and X was noted postoperat ively.Vocal fold paralysis was managed early with endoscopic medialization.
The final pathologic diagnosis was NEe. Metastatic evaluation included computed tomography (CT) of the neck, chest, and abdomen/pelvis, as well as positron emission tomography (PET ); all were negative. PET showed uptake only in th e region of the left temporal bone (figur e 4). Health Environments Research & Design Journal (HERD) is an interdisciplinary, peer-reviewed journal whose mission is to enhance the knowledge and practice of evidence-based healthcare design by disseminating research findings, discussing issues and trends, and translating research to practice.
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. .. The patient was treated with con current che motherapy in two cycles (cisplat in and etoposide) and intens ity-modulated radiation th erapy (IM RT;46 Gy in 23 fra ction s over 5 weeks). Cisplati n was deli vered at a do se of 50 m g/rnvday intravenously on treatme nt days 1, 8, and 29. Etoposide was also administere d at a do se of 50 mg/rnvday intravenously, but on tr eatment days 1 through 5 and 29. Post-treatme nt MRI showed a 1.2 x 0.8-cm lesion at th e ju gular for am en (figure 2, C and D), but th e patient recovered witho ut complication . She was ableto tolerate a general oral diet and dem onstr ated excellent voice recovery at 6 months post-treatment.
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The tumor showed cytologicand architectural features ofNEC ( figure 5 ). Special stains were positive for chro-mogranin and syna pto physin, and negative for S-100 pr ot ein . Histol ogy confirmed -features of dense-core gra nules, tumo r cells separated by fibrous stroma, and cells showing pleomorphism and hyp erch romatism. . Discussion Neuroendocrine differentiation of tumors can occur in any organ. Most NECs occurring in the head and neck ar ise from the larynx o r the salivary glands. 2, 3 We report a case of primary NEC of the jugular foramen . The differential diagnosis for tumors of the jugular for amen includes paragangliomas, schwannomas, meningiomas, chordomas, chondrosarcomas, and metastatic lesions. Patients with tum ors at th is site may present with p ulsat ile tinnitus, hearing loss, aural fullness, hoarseness, and/or dysphagia.
Paragangliomas are tumors that derive from the migration of neural crest cells during fetal development.' Glomus jugulare and glomus tympanicum tumors are both found in the temporal bone. Th e latt er type arises within th e middle ear from paraganglionic cells on th e promontory. Glomus jugulare paragan gliomas arise within the jugular foram en from paraganglionic cell rests associated with cranial nerves IX, X, and XI. The arterial blood supply is typically the ascending pharyngeal artery and th e stylom astoid branch of the occipital artery.I Histologically,these tumors appear highlyvascular and are composed of cluster s (Zellballen, which is German for "cell balls") of chie f cells supported by sustentacular cells and sm all blood vessels.' Paragangliomas are the most common jugular foramen tumors. In a series of 102 patients with jugular foramen tumors, Ramina et al reported that 58 patients (57%) had par agangliomas.'The most common presenting complaints were hearing loss and pulsatile tinnitus. Patients with an actively secreting tumor may have tachycardia, arrhythmia, flushing, or labile hypertension.' Perioperative beta-blo ckad e is therefore critical for the se pati ents.' Treatment options include observation (in patients with minimal sym ptoms), radiation, and surge ry. Radiation th erapy, although a controversial option, m ay be useful for reducing tumor growth in elde rly or debilitated patients, but it m ay change tumor bi olog y. Cole and Beiler describe a case of radi ation-induced mali gn ancy occurring after th e tre atment of benign jugular for amen tumor.' Complete tumor removal by microsurgical techniques is th e treatment of choice.
Schwannomas and meningiomas are the next mo st com m on jugular foramen tumors.' Schwannomas aris e from Schwarm cells in th e nerve she ath. Meningiomas in this region arise from arachnoid cells in the jugular bu lb." Like paragangliomas, most of these lesions are NEC can be confused with paraganglioma based on routine histology alone. Specialized staining patterns help distinguish th ese two tumors. Both NECs and paragangliomas stain for the neuroendocrine markers chromogranin and synaptophysin. 2, 8 Sustentacular cells of paragangliomas stain strongly for S-100 protein." but this staining pattern is not seen in NECs because of their lack of sustentacular cells.
The Ki-67 proliferation inde x was 3 to 5% in our case. Ki-67 protein is expressed in all phases of the cell cycle except Goand serves as a good m arker for proliferation. Studies have shown that higher proliferation rates are associated with shorter disease-free and overall survival rates ."!' The cutoff for high proliferation has not been well established, but patients with an index great er than 20% are considered to be at high risk.r The Ki-67 proliferation index in our case indicates that the patient's tumor is a well-differentiated NEe.
The risk of neurovascular damage when treating tumors ofthe jugular for amen must be discussed preoperativelywith patients. Management entails a thorough preoperative neurotologic examination, with MR and/or 90· www.entjourna l.com CT imaging. Because of the vascularity of these lesions, preoperative angiography is recommended. The utility of a PET scan in evaluating distant metastasis with NEC has been described.P-"
The surgical treatment of jugular foramen tumors includes (1) the intact-canal-wall approach, without facial nerve rerouting; (2) the canal-wall-down approach, without facial nerve rerouting; and (3) the canal -walldown approach, with anterior facial nerve rerouting. I I The first option preserves the structure of the ear, with the possibility of preserving hearing. In this approach, a retrosigmoid craniotomy is performed to expose the posterior fossa dura and jugular foramen. The lateral process of Cl and the posterior border of the jugular foramen are removed to expose the tumor.J This exposure allows extradural and intradural tumor resection. Complete tumor removal may be difficult without lower cranial nerve resection.
Surgical damage oflower cranial nerves was the mos t common complication in the treatment ofthese tumors in one large series .J Our patient had postoperative left vocal fold paralysis and associated aspiration with oral intake. This was managed by early vocal fold medialization, with resolution of her dysphonia and aspiration.
Most studies ofNEC have involved laryngeal NECs . 2 • 3 Primarytreatment for this disease includes the use ofchemotherapyand radiation.Barker et al,in the ir studyof23 patients with NEC of the head and neck, recommended induction chemothe rapy followed by radiation." They showed that con current chemoth erapy did not im prove early response, local control, or survival and th at it was more toxic than induction chem otherapy. Cisplatin . and eto poside have been found to be th e most effective chemoth erapy regim en for treating th ese tumors." Treatment was carefully planned by usin g 3-D CT images of th e patient in conjunction with computeri zed dose calculations to determine th e dose int ensity patt ern that wo uld best confor m to th e tumor sha pe. Since th e patient was treated with IMRT,with the redu ced potent ial for treatment toxicity, concur rent chemothera py was used in this case with min imal system ic toxicity.
Rates oflocal failure tend to be muc h higher with NECs than with sim ilarly sized squamous cell carcinomas.r' :" Distant me tastasis isthe most common pattern offailure, and the brain seems to be a sanctuary for metastatic NEe. Barker et al reported rates of metas tatic disease from prim ary head and neck NEC to the brain at 2 years and 5 years as 25% an d 44%, respectively.14 Most experts recommend combined chemo therapy and radiotherapy as th e in itial treatmen t.
Th e histiogenesis of NEC at the jugular for am en has not been elucida ted . Several previou s studies have dem on strated the pre sence of neuroendo crine cells in normal laryngeal tissue, bu t n o such studies have been performe d at th ejugular foramen.v" Future studies m ay focus on dem on str atin g neuroendocrine cells at th e jugular fora me n by immunohi stochemic al markers.
